Skip to main content
SpringerLink
Log in

Drug persistency of cholinesterase inhibitors for patients with dementia of Alzheimer type in Korea

  • Research Article
  • Published:
Archives of Pharmacal Research Aims and scope Submit manuscript

Abstract

This study examined 1-year persistency with cholinesterase inhibitors (ChEIs) for the treatment of elderly Alzheimer’s dementia (AD) patients in Korea. Korean Health Insurance Review & Assessment Service database from January 2005 to June 2006 was used. Patients aged 65 or older with AD diagnosis who were first prescribed a ChEI were included. The 1-year persistence, persistency rate, and switching patterns during the follow-up period were identified. Mean time to drug discontinuation was analyzed, and persistency rates between different patient factors were compared. The 1-year persistency rate of newly treated 6,461 AD patients was 24.0 %, while 50 % of study patients discontinued treatment by 91 days from initiation. Persistency rates of female patients (22.8 %), patients in rural areas (12.7 %), and primary care (10.2 %) were relatively low (p < 0.001). Persistency rate differed between age groups (p < 0.001). Overall proportion of switching was 6.6 %. The 1-year persistency rate of ChEIs for AD patients in Korea did not reach those of previous researches in other countries. Patients less likely to remain on therapy should be especially monitored to optimize treatment persistence.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  • Abughosh, S.M., and S.J. Kogut. 2008. Comparison of persistence rates of acetylcholine-esterase inhibitors in a state Medicaid program. Patient Preference and Adherence 2: 79–85.

    Article  PubMed Central  PubMed  Google Scholar 

  • Alzheimer’s Association. 2010. 2010 Alzheimer’s disease facts and figures. Alzheimer’s & dementia 6: 158–194.

    Article  Google Scholar 

  • Alzheimer’s Disease International. 2012. World Alzheimer report 2012. London: Alzheimer’s Disease International.

    Google Scholar 

  • Amuah, J.E., D.B. Hogan, M. Eliasziw, A. Supina, P. Beck, W. Downey, and C.J. Maxwell. 2010. Persistence with cholinesterase inhibitor therapy in a population-based cohort of patients with Alzheimer’s disease. Pharmacoepidemiology and Drug Safety 19: 670–679.

    Article  CAS  PubMed  Google Scholar 

  • Brewer, L., K. Bennett, C. McGreevy, and D. Williams. 2013. A population-based study of dosing and persistence with anti-dementia medications. European Journal of Clinical Pharmacology 69: 1467–1475.

    Article  PubMed  Google Scholar 

  • Callahan, C.M., H.C. Hendrie, and W.M. Tierney. 1995. Documentation and evaluation of cognitive impairment in elderly primary care patients. Annals of Internal Medicine 122: 422–429.

    Article  CAS  PubMed  Google Scholar 

  • Cho, M., G. Kim, M. Kim, M. Kim, B. Kim, and S. Kim. 2008. Nationwide study on the prevalence of dementia in Korean elders. Seoul: Seoul National University Hospital.

    Google Scholar 

  • Cummings, J.L., J.C. Frank, D. Cherry, N.D. Kohatsu, B. Kemp, L. Hewett, and B. Mittman. 2002. Guidelines for managing Alzheimer’s disease: Part II. Treatment. American Family Physician 65: 2525–2534.

    Google Scholar 

  • Doody, R.S., D.S. Geldmacher, B. Gordon, C.A. Perdomo, and R.D. Pratt. 2001. Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease. Archives of Neurology 58: 427–433.

    Article  CAS  PubMed  Google Scholar 

  • Dybicz, S.B., D.J. Keohane, W. Erwin, T. Mcrae, and S.N. Shah. 2006. Patterns of cholinesterase-inhibitor use in the nursing home setting: a retrospective analysis. The American Journal of Geriatric Pharmacotherapy 4: 154–160.

    Article  PubMed  Google Scholar 

  • Fillit, H., and J. Hill. 2005. Economics of dementia and pharmacoeconomics of dementia therapy. The American Journal of Geriatric Pharmacotherapy 3: 39–49.

    Article  PubMed  Google Scholar 

  • Gauthier, S., M. Emre, M.R. Farlow, R. Bullock, G.T. Grossberg, and S.G. Potkin. 2003. Strategies for continued successful treatment of Alzheimer’s disease: switching cholinesterase inhibitors. Current Medical Research and Opinion 19: 707–714.

    Article  PubMed  Google Scholar 

  • Herrmann, N., S.S. Gill, C.M. Bell, G.M. Anderson, S.E. Bronskill, K.I. Shulman, H.D. Fischer, K. Sykora, H.S. Shi, and P.A. Rochon. 2007. A population-based study of cholinesterase inhibitor use for dementia. Journal of the American Geriatrics Society 55: 1517–1523.

    Article  PubMed  Google Scholar 

  • Johannsen, P. 2004. Long-term cholinesterase inhibitor treatment of Alzheimer’s disease. CNS drugs 18: 757–768.

    Article  CAS  PubMed  Google Scholar 

  • Johannsen, P., E. Salmon, H. Hampel, Y. Xu, S. Richardson, S. Qvitzau, and R. Schindler. 2006. Assessing therapeutic efficacy in a progressive disease. CNS Drugs 20: 311–325.

    Article  CAS  PubMed  Google Scholar 

  • Joo, K., H. Kim, S. Lee, and H. Min. 1996. A Comparative study on medical utilization between Urban and Rural Korea. Korean Journal of Preventive Medicine 29: 311–330.

    Google Scholar 

  • Kang, S.J., S.J. Yoon, J.H. Jeong, and D.L. Na. 2001. Time interval between the recognition of dementia symptom and the first hospital visit in Alzheimer’s disease. Journal of Korean Neurological Association 19: 62–64.

    Google Scholar 

  • Korean Dementia Association. 2006. Dementia: A clinical approach. Seoul: Academia.

    Google Scholar 

  • Lee, D.W., Y.S. Huh, and K.W. Kim. 2009. Evidence-based treatment of Alzheimer’s disease. Journal of the Korean Medical Association 52: 417–425.

    Article  Google Scholar 

  • Lee, K.S., D.W. Lee, J.Y. Lee, H.K. Cheong, K.R. Kim, J.H. Choi, B.H. Oh, and C.H. Hong. 2006. Analysis of current status of management for dementia between city and country health center. Journal of Korean Geriatric Psychiatry 10: 84–89.

    Google Scholar 

  • Mauskopf, J.A., C. Paramore, W.C. Lee, and E.H. Snyder. 2005. Drug persistency patterns for patients treated with rivastigmine or donepezil in usual care settings. Journal of Managed Care Pharmacy 11: 231–251.

    PubMed  Google Scholar 

  • Mucha, L., S.S. Wang, B. Cuffel, T. Mcrae, T.L. Mark, and M. Del Valle. 2008. Comparison of cholinesterase inhibitor utilization patterns and associated health care costs in Alzheimer’s disease. Journal of Managed Care Pharmacy 14: 451–461.

    PubMed  Google Scholar 

  • O’connor, D., P. Pollitt, J. Hyde, C. Brook, B. Reiss, and M. Roth. 1988. Do general practitioners miss dementia in elderly patients? British Medical Journal 297: 1107–1110.

    Article  PubMed Central  PubMed  Google Scholar 

  • Park, B., J. Sung, K. Park, S. Seo, and S. Kim. 2003. Report of the evaluation for validity of discharged diagnoses in Korean Health Insurance database, 19–52. Seoul: Seoul National University.

    Google Scholar 

  • Rabins, P., D. Blacker, B. Rovner, T. Rummans, L. Schneider, P. Tariot, D. Blass, J. Mcintyre, S. Charles, and D. Anzia. 2007. American Psychiatric Association practice guideline for the treatment of patients with Alzheimer’s disease and other dementias. Arlington: American Psychiatirc Association.

    Google Scholar 

  • Rountree, S.D., A. Atri, O.L. Lopez, and R.S. Doody. 2013. Effectiveness of antidementia drugs in delaying Alzheimer’s disease progression. Alzheimer’s & Dementia 9: 338–345.

    Article  Google Scholar 

  • Sabaté, E. 2003. Adherence to long-term therapies: evidence for action. Geneva: World Health Organization.

    Google Scholar 

  • Sikka, R., F. Xia, and R.E. Aubert. 2005. Estimating medication persistency using administrative claims data. The American Journal of Managed Care 11: 449–457.

    PubMed  Google Scholar 

  • Suh, D.C., S.K. Thomas, E. Valiyeva, S. Arcona, and L. Vo. 2005. Drug persistency of two cholinesterase inhibitors. Drugs and Aging 22: 695–707.

    Article  CAS  PubMed  Google Scholar 

  • Suh, G.H. 2007. Drug therapy for Alzheimer’s disease. Journal of the Korean Medical Association 50: 369–374.

    Article  Google Scholar 

  • Thompson, S., K.L. Lanctôt, and N. Herrmann. 2004. The benefits and risks associated with cholinesterase inhibitor therapy in Alzheimer’s disease. Expert Opinion on Drug Safety 3: 425–440.

    Article  CAS  PubMed  Google Scholar 

  • Wimo, A., B. Winblad, and L. Jonsson. 2007. An estimate of the total worldwide societal costs of dementia in 2005. Alzheimer’s & Dementia 3: 81–91.

    Article  Google Scholar 

  • Winblad, B., and V. Jelic. 2004. Long-term treatment of Alzheimer disease: Efficacy and safety of acetylcholinesterase inhibitors. Alzheimer Disease and Associated Disorders 18(Suppl 1): S2–S8.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

This study was supported by the Ministry of Food and Drug Safety (formerly Korea Food and Drug Administration), Korea (07072 KFDA 224: Drug utilization monitoring for frail population, specific impaired patients, contraindicated drug combinations, age-limited drugs and drugs with narrow therapeutic index).

Conflict of interest

The authors have no conflicts of interest that are directly relevant to the content of this study.

Author information

Authors and Affiliations

  1. Korea Institute of Drug Safety and Risk Management, Seoul, Korea

    So-Hyeon Ahn, Ye-Jee Kim, Jong-Mi Seong, Ju-Young Shin, Sun-Young Jung & Byung-Joo Park

  2. Department of Preventive Medicine, Seoul National University College of Medicine, 103 Daehak-ro, Jongno-gu, Seoul, 110-799, Korea

    So-Hyeon Ahn, Ye-Jee Kim, Jong-Mi Seong, Ju-Young Shin, Sun-Young Jung & Byung-Joo Park

  3. Division of Clinical Epidemiology, Medical Research Collaborating Center, Seoul National University Hospital, Seoul National University College of Medicine, 101 Daehak-ro, Jongno-gu, Seoul, 110-799, Korea

    Nam-Kyong Choi

  4. Medical Research Center, Seoul National University, Seoul, Korea

    Nam-Kyong Choi

Authors
  1. So-Hyeon Ahn
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nam-Kyong Choi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ye-Jee Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jong-Mi Seong
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ju-Young Shin
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Sun-Young Jung
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Byung-Joo Park
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Byung-Joo Park.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ahn, SH., Choi, NK., Kim, YJ. et al. Drug persistency of cholinesterase inhibitors for patients with dementia of Alzheimer type in Korea. Arch. Pharm. Res. 38, 1255–1262 (2015). https://doi.org/10.1007/s12272-014-0500-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12272-014-0500-8

Keywords

Search

Navigation